Press Releases

Valbonne, France, November 7, 2014. – TxCell SA (FR0010127662 – TXCL), a biotechnology company developing innovative, economically viable, personalized T cell immunotherapies using antigen specific regulatory T-cells (Ag-Tregs) for severe chronic inflammatory and autoimmune diseases, announces today that Damian...

TxCell (FR0010127662 - TXCL), a biotechnology company developing innovative, economically viable, personalized T cell immunotherapies using antigen specific regulatory T-cells (Ag-Tregs) for severe chronic inflammatory and autoimmune diseases, today reports its revenues(1) as of September 30, 2014. ...

CARLINA Technologies, a biotechnology company specialized in the development of nanomedicines, today announces the signing of a collaborative agreement with GenBiotech for the development of a prolonged-release pharmaceutical form of a protein. The resultant protein will be used in...

GTx Inc. (NASDAQ: GTXI) today announced that it will host a conference call and webcast to provide a corporate update and discuss the Company's third quarter 2014 financial results on Monday November 10 at 9:00 a.m....

Neurocrine Biosciences to Present at the Nomura Biotechnology ConferenceLive Audio Webcast will be on November 6 2014 PR Newswire SAN DIEGO Nov. 3 2014 SAN DIEGO Nov. 3 2014 /PRNewswire/ -- Neurocrine Biosciences Inc. (Nasdaq: ...

TxCell SA (FR0010127662 – TXCL), a biotechnology company developing innovative, personalized cell-based immunotherapies using antigen specific regulatory T-cells (Ag-Tregs) for severe chronic inflammatory and autoimmune diseases, announces today that Dr. Miguel Forte, Sr. VP Clinical Development and Regulatory Affairs,...

Patheon is to showcase its biologic, small molecule API development services and manufacturing capabilities for finished dosage forms at CPhI / ICSE Worldwide from Tuesday 7 October to Thursday 9 October in Paris Nord Villepinte, France. ...